Contact

About Thabor Therapeutics

Thabor is an INSERM spin off developing a first-in-class therapeutic antibody targeting AGR2 for the treatment of  inflammatory mucosal diseases.

Management Team

Régis Olivier

President/CFO

Read bio
Stéphanie Beq
R&D Director

Stéphanie Beq

R&D Director

Read bio

Laurence de Schoulepnikoff

Executive Chairman

Read bio



Scientific & Clinical Founders

Inserm
Head of U1242 unit (Rennes, France)

Eric Chevet

Head of INSERM U1242 Endoplasmic Reticulum (ER) Biology

Read bio
Inserm
U1242 unit
(Rennes, France)

Eric Ogier-Denis

INSERM U1242
Gut Patho-Physiology

Read bio
Gastroenterologist
Co-founder of Institut des MICI (Paris, France)

Xavier Treton

Gastroenterologist,
Co-founder Institut des MICI

Read bio

Where to find us

BioLabs Hôtel-Dieu
1 Parvis Notre-Dame, Place Jean-Paul II
75004 Paris
France

Headquarters

4 rue Thénard
75005 Paris
France

Linkedin

Copyright 2023 Thabor Therapeutics – Legal mentions

Régis Olivier

Régis brings more than 25 years of experience in the areas of finance, structuring and management of health technology companies. Prior to joining Thabor Therapeutics, Régis was CEO of Axess Vision Technology, a company dedicated to the development of single-use medical endoscopes, where he led the launch of new products and successfully completed new financing rounds. 

Régis is currently CFO of Tridek-One, a biotech start-up developing first-in-class therapeutic agonistic antibodies targeting immune checkpoint inhibitory receptors.

Also former CFO of Echosens, a medical technology company specializing in the non-invasive detection of liver disease, he completed the structuring and sale of the company in 2011. Previously, he held several positions as a financial analyst and financial controller in several industrial companies. Régis holds a Master degree in Management and Finance from EDC Paris.

Stéphanie Beq

Stéphanie spent more than 15 years in immunology / R&D at developing biologics. Before joining Thabor Tx, Stéphanie was R&D Director at Alexion France, and Senior Director at HifiBio, Stallergenes, and Cytheris.


Stéphanie holds a PhD in Medical Virology and got a 4-year post-doctoral position at Pasteur Institute in Nobel Prize laureate Dr. F. Barre-Sinoussi’s laboratory.

Laurence de Schoulepnikoff

Laurence is a seasoned pharma/biotech professional with over 25 years of experience in transactions and R&D operations and general management. She has worked in VC funded biotech start-ups, mid-size private companies as well as large corporate organizations.
Laurence brings a strategic vision for corporate development as well as on company structure and general organization. She has a track record of negotiating and managing numerous transactions, including M&A, in- and out-licensing and collaborations.

Laurence is currently CEO of Tridek-One, a biotech start-up developing first-in-class therapeutic agonistic antibodies targeting immune checkpoint inhibitory receptors.
She is a Venture Partner at AdBio Partners and seats as independent board member in biotech start-ups.
Laurence holds a Master in Chemical Engineering from the Ecole Polytechnique Fédérale of Lausanne (EPFL) and is a board member of the Swiss Healthcare Licensing Group (HLG).

Eric Chevet

Thabor co-founder, Eric Chevet is a biochemist. He is head of INSERM Unit 1242 employing more than 100 researchers dedicated to stress signals in oncology and gastroenterology.

He published more than 200 publications and filed 9 patent applications. He also co-founded Cell Stress Discoveries Ltd.

Eric Ogier-Denis

Thabor co-founder, Eric Ogier-Denis is a translational biologist. He is research director of INSERM Unit 1242. He is an expert in IBD pathophysiology and associated animal models.

He filed 14 patent applications and co-founded Inception IBD, a company financed by Versant Partners.

Xavier Treton

Xavier Treton is a gastroenterologist and co-founder of Institut des MICI. He was the former head of gastrointestinal service and tissue bank at Beaujon Paris hospital, well-known for clinical trials in IBD (APHP, largest European cluster of hospitals).

He co-founded Inception IBD, a company financed by Versant Partners.

He is member of the board of the GETAID, a national association to promote IBD studies in France and Europe with 47 affiliated medical centers.